Nelfinavir - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (1)Enzymes (8)Carriers (1)Transporters (5)

Targets (1)Enzymes (8)Carriers (1)Transporters (5)Biointeractions (19)

Identification

Name

Nelfinavir

Accession Number

DB00220 (APRD00003)

Type

Small Molecule

Groups

Approved

Description

Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Not Available

External IDs

AG1343

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Nelfinavir mesylate	98D603VP8V	159989-65-8	NQHXCOAXSHGTIA-SKXNDZRYSA-N	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Viracept	Tablet, film coated	625 mg/1	Oral	Remedy Repack	2013-03-27	2016-03-11	US
Viracept	Tablet, film coated	250 mg/1	Oral	Agouron Pharmaceuticals	1997-03-14	Not applicable	US
Viracept	Powder	50 mg/g	Oral	Agouron Pharmaceuticals	1997-03-14	2016-02-26	US
Viracept	Tablet	625 mg	Oral	Pfizer	2004-08-11	Not applicable	Canada
Viracept	Tablet, film coated	625 mg/1	Oral	Agouron Pharmaceuticals	2003-04-30	Not applicable	US
Viracept	Tablet, film coated	250 mg/1	Oral	H.J. Harkins Company	1997-03-14	Not applicable	US
Viracept	Tablet, film coated	250 mg/1	Oral	Pd Rx Pharmaceuticals, Inc.	1997-03-14	Not applicable	US
Viracept	Tablet, film coated	625 mg/1	Oral	State of Florida DOH Central Pharmacy	2009-07-01	Not applicable	US
Viracept -250mg	Tablet	250 mg	Oral	Pfizer	1998-09-21	Not applicable	Canada
Viracept -50mg	Powder	50 mg	Oral	Pfizer	1998-09-21	Not applicable	Canada

Approved Generic Prescription Products

Not Available

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Not Available

International Brands

Not Available

Brand mixtures

Not Available

Categories

UNII

HO3OGH5D7I

CAS number

159989-64-7

Weight

Average: 567.782
Monoisotopic: 567.313077633

Chemical Formula

C₃₂H₄₅N₃O₄S

InChI Key

QAGYKUNXZHXKMR-HKWSIXNMSA-N

InChI

InChI=1S/C32H45N3O4S/c1-21-25(15-10-16-28(21)36)30(38)33-26(20-40-24-13-6-5-7-14-24)29(37)19-35-18-23-12-9-8-11-22(23)17-27(35)31(39)34-32(2,3)4/h5-7,10,13-16,22-23,26-27,29,36-37H,8-9,11-12,17-20H2,1-4H3,(H,33,38)(H,34,39)/t22-,23+,26-,27-,29+/m0/s1

IUPAC Name

(3S,4aS,8aS)-N-tert-butyl-2-[(2R,3R)-2-hydroxy-3-[(3-hydroxy-2-methylphenyl)formamido]-4-(phenylsulfanyl)butyl]-decahydroisoquinoline-3-carboxamide

SMILES

[H][C@@]12CCCC[C@]1([H])CN(C[C@@H](O)[[email protected]](CSC1=CC=CC=C1)NC(=O)C1=C(C)C(O)=CC=C1)[C@@H](C2)C(=O)NC(C)(C)C

Pharmacology

Indication

Used in combination with other antiviral drugs in the treatment of HIV in both adults and children.

Structured Indications

HIV-1 Infections

Pharmacodynamics

Nelfinavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Nelfinavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.

Mechanism of action

Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
HIV-1 protease	Protein	yes	inhibitor	Human immunodeficiency virus	O90777	details

Absorption

Well absorbed following oral administration.

Volume of distribution

2 to 7 L/kg

Protein binding

>98%

Metabolism

Primarily hepatic via cytochrome P450 (CYP450) enzymes. CYP3A and CYP2C19 appear to be the predominant enzymes that metabolize nelfinavir in humans. One major and several minor metabolites are found in plasma; the major oxidative metabolite has in vitro antiviral activity comparable to that of the parent drug.

Route of elimination

The terminal half-life in plasma was typically 3.5 to 5 hours. The majority (87%) of an oral 750 mg dose containing 14C-nelfinavir was recovered in the feces; fecal radioactivity consisted of numerous oxidative metabolites (78%) and unchanged nelfinavir (22%). Only 1–2% of the dose was recovered in urine, of which unchanged nelfinavir was the major component.

Half life

3.5 - 5 hours

Clearance

Not Available

Toxicity

Oral LD₅₀ is over 5g/kg in rats. Side effects include thirst and hunger, unexplained weight loss, increased urination, fatigue, and dry, itchy skin.

Affected organisms

Human Immunodeficiency Virus

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
16-Bromoepiandrosterone	The serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Nelfinavir.	Investigational
19-norandrostenedione	The serum concentration of 19-norandrostenedione can be increased when it is combined with Nelfinavir.	Experimental, Illicit
2,4-thiazolidinedione	The therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Nelfinavir.	Investigational
5-androstenedione	The serum concentration of 5-androstenedione can be increased when it is combined with Nelfinavir.	Experimental, Illicit
Abacavir	The serum concentration of Abacavir can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Abiraterone	The metabolism of Abiraterone can be decreased when combined with Nelfinavir.	Approved
Acarbose	The therapeutic efficacy of Acarbose can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Acebutolol	The serum concentration of Acebutolol can be decreased when it is combined with Nelfinavir.	Approved
Acenocoumarol	The metabolism of Acenocoumarol can be decreased when combined with Nelfinavir.	Approved
Acetaminophen	The metabolism of Acetaminophen can be decreased when combined with Nelfinavir.	Approved
Acetohexamide	The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Nelfinavir.	Withdrawn
Acetylsalicylic acid	The serum concentration of Acetylsalicylic acid can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Adinazolam	The metabolism of Adinazolam can be decreased when combined with Nelfinavir.	Approved
Afatinib	The serum concentration of Afatinib can be decreased when it is combined with Nelfinavir.	Approved
AICA ribonucleotide	The therapeutic efficacy of Aicar can be decreased when used in combination with Nelfinavir.	Experimental
Albendazole	The metabolism of Albendazole can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Alclometasone	The metabolism of Alclometasone can be decreased when combined with Nelfinavir.	Approved
Aldosterone	The serum concentration of Aldosterone can be decreased when it is combined with Nelfinavir.	Experimental
Alectinib	The serum concentration of Nelfinavir can be increased when it is combined with Alectinib.	Approved
Alfentanil	The metabolism of Alfentanil can be decreased when combined with Nelfinavir.	Approved, Illicit
Alfuzosin	The serum concentration of Alfuzosin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Aliskiren	The metabolism of Aliskiren can be decreased when combined with Nelfinavir.	Approved, Investigational
Alitretinoin	The serum concentration of Alitretinoin can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Allylestrenol	The metabolism of Allylestrenol can be decreased when combined with Nelfinavir.	Approved
Almotriptan	The serum concentration of Almotriptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Alogliptin	The metabolism of Alogliptin can be decreased when combined with Nelfinavir.	Approved
Alosetron	The serum concentration of Alosetron can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Alprazolam	The serum concentration of Alprazolam can be increased when it is combined with Nelfinavir.	Approved, Illicit, Investigational
Amantadine	The serum concentration of Nelfinavir can be increased when it is combined with Amantadine.	Approved
Ambrisentan	The metabolism of Ambrisentan can be decreased when combined with Nelfinavir.	Approved, Investigational
Ambroxol	The metabolism of Ambroxol can be decreased when combined with Nelfinavir.	Approved
Ambroxol acefyllinate	The serum concentration of Ambroxol acefyllinate can be decreased when it is combined with Nelfinavir.	Experimental
Amcinonide	The serum concentration of Amcinonide can be increased when it is combined with Nelfinavir.	Approved
Amineptine	The serum concentration of Amineptine can be increased when it is combined with Nelfinavir.	Illicit, Withdrawn
Aminohippuric acid	The serum concentration of Nelfinavir can be increased when it is combined with Aminohippuric acid.	Approved
Aminophenazone	The metabolism of Aminophenazone can be decreased when combined with Nelfinavir.	Approved, Withdrawn
Aminophylline	The metabolism of Aminophylline can be decreased when combined with Nelfinavir.	Approved
Amiodarone	The serum concentration of Amiodarone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Amitriptyline	The metabolism of Amitriptyline can be decreased when combined with Nelfinavir.	Approved
Amlodipine	The metabolism of Amlodipine can be decreased when combined with Nelfinavir.	Approved
Amoxicillin	The metabolism of Amoxicillin can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Amprenavir	The metabolism of Amprenavir can be decreased when combined with Nelfinavir.	Approved
Amsacrine	The serum concentration of Nelfinavir can be increased when it is combined with Amsacrine.	Approved
Anagrelide	Nelfinavir may increase the QTc-prolonging activities of Anagrelide.	Approved
Androstenedione	The serum concentration of 4-Androstenedione can be increased when it is combined with Nelfinavir.	Experimental, Illicit
Anecortave	The serum concentration of Anecortave can be increased when it is combined with Nelfinavir.	Investigational
Antipyrine	The metabolism of Antipyrine can be decreased when combined with Nelfinavir.	Approved
Apixaban	The serum concentration of Apixaban can be increased when it is combined with Nelfinavir.	Approved
Apremilast	The metabolism of Apremilast can be decreased when combined with Nelfinavir.	Approved, Investigational
Aprepitant	The serum concentration of Nelfinavir can be increased when it is combined with Aprepitant.	Approved, Investigational
Arformoterol	The metabolism of Arformoterol can be decreased when combined with Nelfinavir.	Approved, Investigational
Argatroban	The metabolism of Argatroban can be decreased when combined with Nelfinavir.	Approved, Investigational
Aripiprazole	The serum concentration of Aripiprazole can be increased when it is combined with Nelfinavir.	Approved, Investigational
Armodafinil	The metabolism of Nelfinavir can be decreased when combined with Armodafinil.	Approved, Investigational
Arsenic trioxide	Nelfinavir may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	The metabolism of Artemether can be decreased when combined with Nelfinavir.	Approved
Asenapine	The serum concentration of Nelfinavir can be decreased when it is combined with Asenapine.	Approved
Astemizole	The serum concentration of Astemizole can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Atazanavir	The metabolism of Atazanavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Atenolol	The serum concentration of Atenolol can be decreased when it is combined with Nelfinavir.	Approved
Atomoxetine	The metabolism of Nelfinavir can be decreased when combined with Atomoxetine.	Approved
Atorvastatin	The serum concentration of Atorvastatin can be increased when it is combined with Nelfinavir.	Approved
Avanafil	The serum concentration of Avanafil can be increased when it is combined with Nelfinavir.	Approved
Axitinib	The serum concentration of Axitinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Azelastine	The metabolism of Azelastine can be decreased when combined with Nelfinavir.	Approved
Azithromycin	The metabolism of Azithromycin can be decreased when combined with Nelfinavir.	Approved
Azithromycin	The serum concentration of Azithromycin can be increased when it is combined with Nelfinavir.	Approved
Balaglitazone	The therapeutic efficacy of Balaglitazone can be decreased when used in combination with Nelfinavir.	Investigational
Banoxantrone	The metabolism of Banoxantrone can be decreased when combined with Nelfinavir.	Investigational
Barnidipine	The serum concentration of Barnidipine can be increased when it is combined with Nelfinavir.	Approved
Beclomethasone dipropionate	The serum concentration of Beclomethasone dipropionate can be increased when it is combined with Nelfinavir.	Approved, Investigational
Bedaquiline	The serum concentration of Bedaquiline can be increased when it is combined with Nelfinavir.	Approved
Benzatropine	The metabolism of Benzatropine can be decreased when combined with Nelfinavir.	Approved
Benzocaine	The serum concentration of Nelfinavir can be increased when it is combined with Benzocaine.	Approved
Benzphetamine	The metabolism of Benzphetamine can be decreased when combined with Nelfinavir.	Approved, Illicit
Benzyl alcohol	The metabolism of Benzyl alcohol can be decreased when combined with Nelfinavir.	Approved
Bepridil	The serum concentration of Nelfinavir can be increased when it is combined with Bepridil.	Approved, Withdrawn
Betamethasone	The serum concentration of Betamethasone can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Bexarotene	The metabolism of Bexarotene can be decreased when combined with Nelfinavir.	Approved, Investigational
Bezafibrate	The metabolism of Bezafibrate can be decreased when combined with Nelfinavir.	Approved
Bicalutamide	The metabolism of Bicalutamide can be decreased when combined with Nelfinavir.	Approved
Biperiden	The serum concentration of Nelfinavir can be increased when it is combined with Biperiden.	Approved
Bisoprolol	The metabolism of Bisoprolol can be decreased when combined with Nelfinavir.	Approved
Boceprevir	The serum concentration of Nelfinavir can be decreased when it is combined with Boceprevir.	Withdrawn
Bortezomib	The serum concentration of Bortezomib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Bosentan	The serum concentration of Bosentan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Bosutinib	The serum concentration of Bosutinib can be increased when it is combined with Nelfinavir.	Approved
Brentuximab vedotin	The serum concentration of Brentuximab vedotin can be increased when it is combined with Nelfinavir.	Approved
Brexpiprazole	The serum concentration of Brexpiprazole can be increased when it is combined with Nelfinavir.	Approved
Brinzolamide	The serum concentration of Brinzolamide can be increased when it is combined with Nelfinavir.	Approved
Bromazepam	The metabolism of Bromazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Bromocriptine	The serum concentration of Bromocriptine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Brompheniramine	The metabolism of Brompheniramine can be decreased when combined with Nelfinavir.	Approved
Budesonide	The serum concentration of Budesonide can be increased when it is combined with Nelfinavir.	Approved
Budesonide	The metabolism of Budesonide can be decreased when combined with Nelfinavir.	Approved
Buformin	The therapeutic efficacy of Buformin can be decreased when used in combination with Nelfinavir.	Withdrawn
Bupivacaine	The metabolism of Bupivacaine can be decreased when combined with Nelfinavir.	Approved, Investigational
Buprenorphine	The metabolism of Buprenorphine can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational, Vet Approved
Bupropion	The metabolism of Bupropion can be decreased when combined with Nelfinavir.	Approved
Buspirone	The metabolism of Buspirone can be decreased when combined with Nelfinavir.	Approved, Investigational
Busulfan	The metabolism of Busulfan can be decreased when combined with Nelfinavir.	Approved, Investigational
Cabazitaxel	The serum concentration of Cabazitaxel can be increased when it is combined with Nelfinavir.	Approved
Cabergoline	The serum concentration of Cabergoline can be increased when it is combined with Nelfinavir.	Approved
Cabozantinib	The serum concentration of Cabozantinib can be increased when it is combined with Nelfinavir.	Approved
Caffeine	The metabolism of Caffeine can be decreased when combined with Nelfinavir.	Approved
Calcitriol	The metabolism of Calcitriol can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Camptothecin	The serum concentration of Camptothecin can be decreased when it is combined with Nelfinavir.	Experimental
Canagliflozin	The metabolism of Canagliflozin can be decreased when combined with Nelfinavir.	Approved
Candesartan	The serum concentration of Nelfinavir can be increased when it is combined with Candesartan.	Approved
Captopril	The serum concentration of Nelfinavir can be increased when it is combined with Captopril.	Approved
Carbamazepine	The metabolism of Nelfinavir can be increased when combined with Carbamazepine.	Approved, Investigational
Carbinoxamine	The metabolism of Carbinoxamine can be decreased when combined with Nelfinavir.	Approved
Carfilzomib	The serum concentration of Carfilzomib can be decreased when it is combined with Nelfinavir.	Approved
Cariprazine	The metabolism of Cariprazine can be decreased when combined with Nelfinavir.	Approved
Carisoprodol	The metabolism of Carisoprodol can be decreased when combined with Nelfinavir.	Approved
Carvedilol	The metabolism of Carvedilol can be decreased when combined with Nelfinavir.	Approved, Investigational
Caspofungin	The serum concentration of Nelfinavir can be increased when it is combined with Caspofungin.	Approved
Castanospermine	The therapeutic efficacy of Castanospermine can be decreased when used in combination with Nelfinavir.	Experimental
Celecoxib	The metabolism of Celecoxib can be decreased when combined with Nelfinavir.	Approved, Investigational
Celiprolol	The metabolism of Celiprolol can be decreased when combined with Nelfinavir.	Approved, Investigational
Cephalexin	The metabolism of Cephalexin can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Ceritinib	The serum concentration of Ceritinib can be increased when it is combined with Nelfinavir.	Approved
Cerivastatin	The metabolism of Cerivastatin can be decreased when combined with Nelfinavir.	Withdrawn
Cevimeline	The metabolism of Cevimeline can be decreased when combined with Nelfinavir.	Approved
Chenodeoxycholic acid	The metabolism of Chenodeoxycholic acid can be decreased when combined with Nelfinavir.	Approved
Chloramphenicol	The metabolism of Nelfinavir can be decreased when combined with Chloramphenicol.	Approved, Vet Approved
Chlordiazepoxide	The metabolism of Chlordiazepoxide can be decreased when combined with Nelfinavir.	Approved, Illicit
Chloroquine	The metabolism of Chloroquine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Chlorotrianisene	The serum concentration of Chlorotrianisene can be decreased when it is combined with Nelfinavir.	Withdrawn
Chlorphenamine	The metabolism of Chlorphenamine can be decreased when combined with Nelfinavir.	Approved
Chlorpromazine	The metabolism of Chlorpromazine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Chlorpropamide	The serum concentration of Nelfinavir can be increased when it is combined with Chlorpropamide.	Approved
Chlorprothixene	The serum concentration of Nelfinavir can be increased when it is combined with Chlorprothixene.	Approved, Withdrawn
Chlorzoxazone	The metabolism of Chlorzoxazone can be decreased when combined with Nelfinavir.	Approved
Cholecalciferol	The metabolism of Cholecalciferol can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Cholesterol	The serum concentration of Nelfinavir can be increased when it is combined with Cholesterol.	Experimental
Cholic Acid	The serum concentration of Nelfinavir can be decreased when it is combined with Cholic Acid.	Approved
Ciclesonide	The metabolism of Ciclesonide can be decreased when combined with Nelfinavir.	Approved, Investigational
Ciglitazone	The therapeutic efficacy of Ciglitazone can be decreased when used in combination with Nelfinavir.	Experimental
Cilazapril	The serum concentration of Nelfinavir can be increased when it is combined with Cilazapril.	Approved
Cilostazol	The serum concentration of Cilostazol can be increased when it is combined with Nelfinavir.	Approved
Cimetidine	The serum concentration of Nelfinavir can be decreased when it is combined with Cimetidine.	Approved
Cinacalcet	The metabolism of Cinacalcet can be decreased when combined with Nelfinavir.	Approved
Ciprofloxacin	Nelfinavir may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	The serum concentration of Cisapride can be increased when it is combined with Nelfinavir.	Approved, Investigational, Withdrawn
Cisplatin	The serum concentration of Cisplatin can be decreased when it is combined with Nelfinavir.	Approved
Citalopram	The serum concentration of Citalopram can be increased when it is combined with Nelfinavir.	Approved
Clarithromycin	The therapeutic efficacy of Clarithromycin can be decreased when used in combination with Nelfinavir.	Approved
Clemastine	The metabolism of Nelfinavir can be decreased when combined with Clemastine.	Approved
Clindamycin	The metabolism of Clindamycin can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Clobazam	The metabolism of Clobazam can be decreased when combined with Nelfinavir.	Approved, Illicit
Clobetasol	The serum concentration of Clobetasol can be increased when it is combined with Nelfinavir.	Investigational
Clobetasol propionate	The serum concentration of Clobetasol propionate can be increased when it is combined with Nelfinavir.	Approved
Clocortolone	The serum concentration of Clocortolone can be increased when it is combined with Nelfinavir.	Approved
Clofazimine	The metabolism of Clofazimine can be decreased when combined with Nelfinavir.	Approved, Investigational
Clofibrate	The metabolism of Clofibrate can be decreased when combined with Nelfinavir.	Approved
Clomifene	The serum concentration of Clomifene can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Clomipramine	The metabolism of Clomipramine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Clonazepam	The metabolism of Clonazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Clonidine	The metabolism of Clonidine can be decreased when combined with Nelfinavir.	Approved
Clopidogrel	The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved, Nutraceutical
Clorazepate	The metabolism of Clorazepate can be decreased when combined with Nelfinavir.	Approved, Illicit
Clotiazepam	The metabolism of Clotiazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Clotrimazole	The metabolism of Nelfinavir can be decreased when combined with Clotrimazole.	Approved, Vet Approved
Clozapine	The metabolism of Clozapine can be decreased when combined with Nelfinavir.	Approved
Cobicistat	The metabolism of Nelfinavir can be decreased when combined with Cobicistat.	Approved
Cobimetinib	The serum concentration of Cobimetinib can be increased when it is combined with Nelfinavir.	Approved
Cocaine	The metabolism of Cocaine can be decreased when combined with Nelfinavir.	Approved, Illicit
Codeine	The metabolism of Codeine can be decreased when combined with Nelfinavir.	Approved, Illicit
Colchicine	The serum concentration of Colchicine can be increased when it is combined with Nelfinavir.	Approved
Colforsin	The serum concentration of Nelfinavir can be increased when it is combined with Colforsin.	Experimental
Conivaptan	The serum concentration of Conivaptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Conjugated estrogens	The metabolism of Conjugated Equine Estrogens can be decreased when combined with Nelfinavir.	Approved
Cortisone acetate	The metabolism of Cortisone acetate can be decreased when combined with Nelfinavir.	Approved
Crizotinib	The serum concentration of Crizotinib can be increased when it is combined with Nelfinavir.	Approved
Cyclobenzaprine	The metabolism of Cyclobenzaprine can be decreased when combined with Nelfinavir.	Approved
Cyclophosphamide	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Cyclophosphamide.	Approved, Investigational
Cyclosporine	The serum concentration of Cyclosporine can be increased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Cyclosporine	The metabolism of Cyclosporine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Cytarabine	The metabolism of Cytarabine can be decreased when combined with Nelfinavir.	Approved, Investigational
Dabigatran etexilate	The serum concentration of Dabigatran etexilate can be decreased when it is combined with Nelfinavir.	Approved
Dabrafenib	The serum concentration of Nelfinavir can be decreased when it is combined with Dabrafenib.	Approved
Daclatasvir	The serum concentration of Daclatasvir can be increased when it is combined with Nelfinavir.	Approved
Dactinomycin	The serum concentration of Dactinomycin can be decreased when it is combined with Nelfinavir.	Approved
Dantrolene	The metabolism of Dantrolene can be decreased when combined with Nelfinavir.	Approved
Dapagliflozin	The metabolism of Dapagliflozin can be decreased when combined with Nelfinavir.	Approved
Dapoxetine	The serum concentration of Dapoxetine can be increased when it is combined with Nelfinavir.	Investigational
Dapsone	The metabolism of Dapsone can be decreased when combined with Nelfinavir.	Approved, Investigational
Darifenacin	The metabolism of Darifenacin can be decreased when combined with Nelfinavir.	Approved, Investigational
Darunavir	The metabolism of Darunavir can be decreased when combined with Nelfinavir.	Approved
Dasabuvir	The metabolism of Dasabuvir can be decreased when combined with Nelfinavir.	Approved
Dasatinib	The serum concentration of Dasatinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Daunorubicin	The metabolism of Daunorubicin can be decreased when combined with Nelfinavir.	Approved
Debrisoquin	The serum concentration of Debrisoquin can be decreased when it is combined with Nelfinavir.	Approved
Deferasirox	The serum concentration of Nelfinavir can be decreased when it is combined with Deferasirox.	Approved, Investigational
Delavirdine	The serum concentration of Delavirdine can be decreased when it is combined with Nelfinavir.	Approved
Deoxyspergualin	The therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Nelfinavir.	Investigational
Desipramine	The serum concentration of Desipramine can be increased when it is combined with Nelfinavir.	Approved
Desloratadine	The serum concentration of Nelfinavir can be increased when it is combined with Desloratadine.	Approved, Investigational
Desogestrel	The serum concentration of Desogestrel can be decreased when it is combined with Nelfinavir.	Approved
Desoximetasone	The serum concentration of Desoximetasone can be increased when it is combined with Nelfinavir.	Approved
Desoxycorticosterone Pivalate	The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Nelfinavir.	Experimental, Vet Approved
Desvenlafaxine	The metabolism of Desvenlafaxine can be decreased when combined with Nelfinavir.	Approved
Dexamethasone	The metabolism of Dexamethasone can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Dexlansoprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with TAK-390MR resulting in a loss in efficacy.	Approved
Dextromethorphan	The metabolism of Dextromethorphan can be decreased when combined with Nelfinavir.	Approved
Dextropropoxyphene	The metabolism of Dextropropoxyphene can be decreased when combined with Nelfinavir.	Approved, Illicit, Withdrawn
Diazepam	The metabolism of Diazepam can be decreased when combined with Nelfinavir.	Approved, Illicit, Vet Approved
Diclofenac	The metabolism of Diclofenac can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Dienestrol	The serum concentration of Dienestrol can be decreased when it is combined with Nelfinavir.	Approved
Dienogest	The serum concentration of Dienogest can be decreased when it is combined with Nelfinavir.	Approved
Diethylstilbestrol	The serum concentration of Diethylstilbestrol can be decreased when it is combined with Nelfinavir.	Approved
Diflorasone	The serum concentration of Diflorasone can be increased when it is combined with Nelfinavir.	Approved
Difluocortolone	The serum concentration of Difluocortolone can be increased when it is combined with Nelfinavir.	Approved
Difluprednate	The serum concentration of Difluprednate can be increased when it is combined with Nelfinavir.	Approved
Digitoxin	The metabolism of Digitoxin can be decreased when combined with Nelfinavir.	Approved
Digoxin	The serum concentration of Digoxin can be increased when it is combined with Nelfinavir.	Approved
Dihydrocodeine	The metabolism of Dihydrocodeine can be decreased when combined with Nelfinavir.	Approved, Illicit
Dihydroergotamine	The serum concentration of Dihydroergotamine can be increased when it is combined with Nelfinavir.	Approved
Dihydrotestosterone	The serum concentration of Dihydrotestosterone can be decreased when it is combined with Nelfinavir.	Illicit
Diltiazem	The metabolism of Diltiazem can be decreased when combined with Nelfinavir.	Approved
Diphenhydramine	The metabolism of Diphenhydramine can be decreased when combined with Nelfinavir.	Approved
Dipyridamole	The serum concentration of Dipyridamole can be decreased when it is combined with Nelfinavir.	Approved
Disopyramide	The metabolism of Disopyramide can be decreased when combined with Nelfinavir.	Approved
Disulfiram	The metabolism of Disulfiram can be decreased when combined with Nelfinavir.	Approved
Docetaxel	The metabolism of Docetaxel can be decreased when combined with Nelfinavir.	Approved, Investigational
Dofetilide	The serum concentration of Dofetilide can be increased when it is combined with Nelfinavir.	Approved
Dolasetron	The metabolism of Dolasetron can be decreased when combined with Nelfinavir.	Approved
Domperidone	The serum concentration of Domperidone can be increased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Donepezil	The metabolism of Donepezil can be decreased when combined with Nelfinavir.	Approved
Dopamine	The metabolism of Dopamine can be decreased when combined with Nelfinavir.	Approved
Dorzolamide	The metabolism of Dorzolamide can be decreased when combined with Nelfinavir.	Approved
Dosulepin	The serum concentration of Dosulepin can be increased when it is combined with Nelfinavir.	Approved
Doxazosin	The serum concentration of Nelfinavir can be increased when it is combined with Doxazosin.	Approved
Doxepin	The serum concentration of Nelfinavir can be decreased when it is combined with Doxepin.	Approved
Doxorubicin	The serum concentration of Doxorubicin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Doxorubicin	The metabolism of Doxorubicin can be decreased when combined with Nelfinavir.	Approved, Investigational
Doxycycline	The metabolism of Nelfinavir can be decreased when combined with Doxycycline.	Approved, Investigational, Vet Approved
Dronabinol	The serum concentration of Dronabinol can be increased when it is combined with Nelfinavir.	Approved, Illicit
Dronedarone	The serum concentration of Dronedarone can be increased when it is combined with Nelfinavir.	Approved
Droperidol	Nelfinavir may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Drospirenone	The serum concentration of Drospirenone can be decreased when it is combined with Nelfinavir.	Approved
Dulaglutide	The therapeutic efficacy of Dulaglutide can be decreased when used in combination with Nelfinavir.	Approved
Dutasteride	The serum concentration of Dutasteride can be increased when it is combined with Nelfinavir.	Approved, Investigational
Dyphylline	The serum concentration of Dyphylline can be decreased when it is combined with Nelfinavir.	Approved
Edoxaban	The serum concentration of Edoxaban can be increased when it is combined with Nelfinavir.	Approved
Efavirenz	The metabolism of Efavirenz can be decreased when combined with Nelfinavir.	Approved, Investigational
Elbasvir	The serum concentration of Nelfinavir can be increased when it is combined with Elbasvir.	Approved
Eletriptan	The serum concentration of Eletriptan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Eliglustat	The serum concentration of Eliglustat can be increased when it is combined with Nelfinavir.	Approved
Elvitegravir	The metabolism of Elvitegravir can be decreased when combined with Nelfinavir.	Approved
Empagliflozin	The therapeutic efficacy of Empagliflozin can be decreased when used in combination with Nelfinavir.	Approved
Enalapril	The metabolism of Enalapril can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Enfuvirtide	The serum concentration of Enfuvirtide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Enzalutamide	The serum concentration of Nelfinavir can be decreased when it is combined with Enzalutamide.	Approved
Epinastine	The serum concentration of Nelfinavir can be decreased when it is combined with Epinastine.	Approved, Investigational
Eplerenone	The serum concentration of Eplerenone can be increased when it is combined with Nelfinavir.	Approved
Equilenin	The serum concentration of Equilenin can be increased when it is combined with Nelfinavir.	Experimental
Equilin	The serum concentration of Equilin can be increased when it is combined with Nelfinavir.	Approved
Ergocalciferol	The metabolism of Ergocalciferol can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Ergoloid mesylate	The serum concentration of Ergoloid mesylate can be increased when it is combined with Nelfinavir.	Approved
Ergonovine	The serum concentration of Ergonovine can be increased when it is combined with Nelfinavir.	Approved
Ergotamine	The serum concentration of Ergotamine can be increased when it is combined with Nelfinavir.	Approved
Erlotinib	The serum concentration of Erlotinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Erythromycin	The metabolism of Erythromycin can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Escitalopram	The metabolism of Escitalopram can be decreased when combined with Nelfinavir.	Approved, Investigational
Eslicarbazepine acetate	The serum concentration of Nelfinavir can be decreased when it is combined with Eslicarbazepine acetate.	Approved
Esmirtazapine	The serum concentration of Esmirtazapine can be increased when it is combined with Nelfinavir.	Investigational
Esomeprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Esomeprazole resulting in a loss in efficacy.	Approved, Investigational
Estazolam	The serum concentration of Estazolam can be increased when it is combined with Nelfinavir.	Approved, Illicit
Estradiol	The metabolism of Estradiol can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Estramustine	The metabolism of Estramustine can be decreased when combined with Nelfinavir.	Approved
Estriol	The serum concentration of Estriol can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Estrogens, esterified	The serum concentration of Estrogens, esterified can be decreased when it is combined with Nelfinavir.	Approved
Estrone	The metabolism of Estrone can be decreased when combined with Nelfinavir.	Approved
Estrone sulfate	The metabolism of Estrone sulfate can be decreased when combined with Nelfinavir.	Approved
Eszopiclone	The metabolism of Eszopiclone can be decreased when combined with Nelfinavir.	Approved
Ethanol	The metabolism of Ethanol can be decreased when combined with Nelfinavir.	Approved
Ethinyl Estradiol	The metabolism of Ethinyl Estradiol can be decreased when combined with Nelfinavir.	Approved
Ethosuximide	The metabolism of Ethosuximide can be decreased when combined with Nelfinavir.	Approved
Ethylmorphine	The metabolism of Ethylmorphine can be decreased when combined with Nelfinavir.	Approved, Illicit
Ethynodiol diacetate	The serum concentration of Ethynodiol diacetate can be decreased when it is combined with Nelfinavir.	Approved
Etizolam	The serum concentration of Etizolam can be increased when it is combined with Nelfinavir.	Approved
Etonogestrel	The serum concentration of Etonogestrel can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Etoposide	The metabolism of Etoposide can be decreased when combined with Nelfinavir.	Approved
Etoricoxib	The metabolism of Etoricoxib can be decreased when combined with Nelfinavir.	Approved, Investigational
Etravirine	The serum concentration of Etravirine can be decreased when it is combined with Nelfinavir.	Approved
Everolimus	The serum concentration of Everolimus can be increased when it is combined with Nelfinavir.	Approved
Exemestane	The metabolism of Exemestane can be decreased when combined with Nelfinavir.	Approved, Investigational
Exenatide	The therapeutic efficacy of Exenatide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Ezetimibe	The serum concentration of Ezetimibe can be decreased when it is combined with Nelfinavir.	Approved
Famciclovir	The metabolism of Famciclovir can be decreased when combined with Nelfinavir.	Approved
Famotidine	The serum concentration of Nelfinavir can be decreased when it is combined with Famotidine.	Approved
Felbamate	The metabolism of Felbamate can be decreased when combined with Nelfinavir.	Approved
Felodipine	The metabolism of Felodipine can be decreased when combined with Nelfinavir.	Approved, Investigational
Fenofibrate	The metabolism of Fenofibrate can be decreased when combined with Nelfinavir.	Approved
Fentanyl	The serum concentration of Fentanyl can be increased when it is combined with Nelfinavir.	Approved, Illicit, Investigational, Vet Approved
Fesoterodine	The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Nelfinavir.	Approved
Fexofenadine	The serum concentration of Fexofenadine can be decreased when it is combined with Nelfinavir.	Approved
Fidaxomicin	The serum concentration of Fidaxomicin can be decreased when it is combined with Nelfinavir.	Approved
Finasteride	The metabolism of Finasteride can be decreased when combined with Nelfinavir.	Approved
Fingolimod	The metabolism of Fingolimod can be decreased when combined with Nelfinavir.	Approved, Investigational
Flecainide	Nelfinavir may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Flibanserin	The serum concentration of Flibanserin can be increased when it is combined with Nelfinavir.	Approved
Fluconazole	The metabolism of Nelfinavir can be decreased when combined with Fluconazole.	Approved
Fludrocortisone	The serum concentration of Fludrocortisone can be increased when it is combined with Nelfinavir.	Approved
Flumethasone	The serum concentration of Flumethasone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Flunisolide	The metabolism of Flunisolide can be decreased when combined with Nelfinavir.	Approved, Investigational
Flunitrazepam	The metabolism of Flunitrazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Fluocinolone Acetonide	The serum concentration of Fluocinolone Acetonide can be increased when it is combined with Nelfinavir.	Approved, Investigational, Vet Approved
Fluocinonide	The serum concentration of Fluocinonide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Fluocortolone	The serum concentration of Fluocortolone can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Fluorometholone	The metabolism of Fluorometholone can be decreased when combined with Nelfinavir.	Approved
Fluoxetine	The metabolism of Fluoxetine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Flupentixol	Nelfinavir may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Fluphenazine	The serum concentration of Nelfinavir can be increased when it is combined with Fluphenazine.	Approved
Fluprednidene	The serum concentration of Fluprednidene can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Flurandrenolide	The serum concentration of Flurandrenolide can be increased when it is combined with Nelfinavir.	Approved
Flurazepam	The metabolism of Flurazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Flutamide	The metabolism of Flutamide can be decreased when combined with Nelfinavir.	Approved
Fluticasone furoate	The metabolism of Fluticasone furoate can be decreased when combined with Nelfinavir.	Approved
Fluticasone propionate	The serum concentration of Fluticasone Propionate can be increased when it is combined with Nelfinavir.	Approved
Fluticasone propionate	The metabolism of Fluticasone Propionate can be decreased when combined with Nelfinavir.	Approved
Fluvastatin	The metabolism of Fluvastatin can be decreased when combined with Nelfinavir.	Approved
Fluvoxamine	The metabolism of Nelfinavir can be decreased when combined with Fluvoxamine.	Approved, Investigational
Formestane	The serum concentration of Formestane can be increased when it is combined with Nelfinavir.	Approved, Investigational, Withdrawn
Formoterol	The metabolism of Formoterol can be decreased when combined with Nelfinavir.	Approved, Investigational
Fosamprenavir	The metabolism of Fosamprenavir can be decreased when combined with Nelfinavir.	Approved
Fosaprepitant	The serum concentration of Nelfinavir can be increased when it is combined with Fosaprepitant.	Approved
Fosphenytoin	The serum concentration of Nelfinavir can be decreased when it is combined with Fosphenytoin.	Approved
Fulvestrant	The metabolism of Fulvestrant can be decreased when combined with Nelfinavir.	Approved, Investigational
Fusidic Acid	The serum concentration of Nelfinavir can be increased when it is combined with Fusidic Acid.	Approved
Gadobenic acid	Nelfinavir may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Galantamine	The metabolism of Galantamine can be decreased when combined with Nelfinavir.	Approved
Gefitinib	The metabolism of Gefitinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Gemcitabine	The serum concentration of Gemcitabine can be decreased when it is combined with Nelfinavir.	Approved
Gemfibrozil	The metabolism of Gemfibrozil can be decreased when combined with Nelfinavir.	Approved
Gemifloxacin	Nelfinavir may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Genistein	The serum concentration of Nelfinavir can be increased when it is combined with Genistein.	Investigational
Gestodene	The serum concentration of Gestodene can be decreased when it is combined with Nelfinavir.	Approved
Glibornuride	The therapeutic efficacy of Glibornuride can be decreased when used in combination with Nelfinavir.	Withdrawn
Gliclazide	The metabolism of Gliclazide can be decreased when combined with Nelfinavir.	Approved
Glimepiride	The therapeutic efficacy of Glimepiride can be decreased when used in combination with Nelfinavir.	Approved
Glipizide	The metabolism of Glipizide can be decreased when combined with Nelfinavir.	Approved
Gliquidone	The therapeutic efficacy of Gliquidone can be decreased when used in combination with Nelfinavir.	Approved
Glucosamine	The metabolism of Glucosamine can be decreased when combined with Nelfinavir.	Approved
Glyburide	The metabolism of Glyburide can be decreased when combined with Nelfinavir.	Approved
Goserelin	Nelfinavir may increase the QTc-prolonging activities of Goserelin.	Approved
Gramicidin D	The serum concentration of Nelfinavir can be increased when it is combined with Gramicidin D.	Approved
Granisetron	The metabolism of Granisetron can be decreased when combined with Nelfinavir.	Approved, Investigational
Grazoprevir	The serum concentration of Grazoprevir can be decreased when it is combined with Nelfinavir.	Approved
Grepafloxacin	The metabolism of Grepafloxacin can be decreased when combined with Nelfinavir.	Withdrawn
Guanfacine	The serum concentration of Guanfacine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Gusperimus	The therapeutic efficacy of Gusperimus can be decreased when used in combination with Nelfinavir.	Investigational
Halofantrine	The serum concentration of Halofantrine can be increased when it is combined with Nelfinavir.	Approved
Haloperidol	The metabolism of Haloperidol can be decreased when combined with Nelfinavir.	Approved
Halothane	The metabolism of Halothane can be decreased when combined with Nelfinavir.	Approved, Vet Approved
HE3286	The serum concentration of HE3286 can be increased when it is combined with Nelfinavir.	Investigational
Hexestrol	The serum concentration of Hexestrol can be decreased when it is combined with Nelfinavir.	Withdrawn
Hexobarbital	The metabolism of Hexobarbital can be decreased when combined with Nelfinavir.	Approved
Histamine	The metabolism of Histamine Phosphate can be decreased when combined with Nelfinavir.	Approved, Investigational
Hydrocodone	The serum concentration of Hydrocodone can be increased when it is combined with Nelfinavir.	Approved, Illicit
Hydrocortisone	The metabolism of Hydrocortisone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Hydromorphone	The metabolism of Hydromorphone can be decreased when combined with Nelfinavir.	Approved, Illicit
Hydroxyprogesterone caproate	The metabolism of Hydroxyprogesterone caproate can be decreased when combined with Nelfinavir.	Approved
Ibrutinib	The serum concentration of Ibrutinib can be increased when it is combined with Nelfinavir.	Approved
Ibuprofen	The serum concentration of Ibuprofen can be decreased when it is combined with Nelfinavir.	Approved
Ibutilide	Nelfinavir may increase the QTc-prolonging activities of Ibutilide.	Approved
Idelalisib	The serum concentration of Nelfinavir can be increased when it is combined with Idelalisib.	Approved
Ifosfamide	The serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Iloperidone	The serum concentration of the active metabolites of Iloperidone can be increased when Iloperidone is used in combination with Nelfinavir.	Approved
Imatinib	The serum concentration of Imatinib can be increased when it is combined with Nelfinavir.	Approved
Imidafenacin	The serum concentration of Imidafenacin can be increased when it is combined with Nelfinavir.	Approved
Imipramine	The metabolism of Imipramine can be decreased when combined with Nelfinavir.	Approved
Imiquimod	The metabolism of Imiquimod can be decreased when combined with Nelfinavir.	Approved, Investigational
Indacaterol	The metabolism of Indacaterol can be decreased when combined with Nelfinavir.	Approved
Indapamide	The metabolism of Indapamide can be decreased when combined with Nelfinavir.	Approved
Indinavir	The metabolism of Indinavir can be decreased when combined with Nelfinavir.	Approved
Indomethacin	The serum concentration of Indomethacin can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Insulin Aspart	The therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Nelfinavir.	Approved
Insulin Detemir	The therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Nelfinavir.	Approved
Insulin Glargine	The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Nelfinavir.	Approved
Insulin Glulisine	The therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Nelfinavir.	Approved
Insulin Lispro	The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Nelfinavir.	Approved
Insulin Pork	The therapeutic efficacy of Insulin Pork can be decreased when used in combination with Nelfinavir.	Approved
Ipratropium bromide	The metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir.	Approved
Irinotecan	The serum concentration of the active metabolites of Irinotecan can be increased when Irinotecan is used in combination with Nelfinavir.	Approved, Investigational
Isavuconazonium	The serum concentration of the active metabolites of Isavuconazonium can be increased when Isavuconazonium is used in combination with Nelfinavir.	Approved, Investigational
Isoniazid	The metabolism of Nelfinavir can be decreased when combined with Isoniazid.	Approved
Isosorbide Dinitrate	The metabolism of Isosorbide Dinitrate can be decreased when combined with Nelfinavir.	Approved
Isosorbide Mononitrate	The metabolism of Isosorbide Mononitrate can be decreased when combined with Nelfinavir.	Approved
Isradipine	The metabolism of Isradipine can be decreased when combined with Nelfinavir.	Approved
Itraconazole	The metabolism of Itraconazole can be decreased when combined with Nelfinavir.	Approved, Investigational
Ivabradine	The serum concentration of Ivabradine can be increased when it is combined with Nelfinavir.	Approved
Ivacaftor	The serum concentration of Ivacaftor can be increased when it is combined with Nelfinavir.	Approved
Ivermectin	The metabolism of Ivermectin can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Ixabepilone	The serum concentration of Ixabepilone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ixazomib	The metabolism of Ixazomib can be decreased when combined with Nelfinavir.	Approved
Ketamine	The metabolism of Ketamine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Ketazolam	The metabolism of Ketazolam can be decreased when combined with Nelfinavir.	Approved
Ketobemidone	The metabolism of Ketobemidone can be decreased when combined with Nelfinavir.	Approved
Ketoconazole	The metabolism of Ketoconazole can be decreased when combined with Nelfinavir.	Approved, Investigational
Lacosamide	The serum concentration of Lacosamide can be increased when it is combined with Nelfinavir.	Approved
Lamivudine	The serum concentration of Lamivudine can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Lamotrigine	The serum concentration of Lamotrigine can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Lansoprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Lansoprazole resulting in a loss in efficacy.	Approved, Investigational
Lapatinib	The serum concentration of Lapatinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Laquinimod	The metabolism of Laquinimod can be decreased when combined with Nelfinavir.	Investigational
Ledipasvir	The serum concentration of Ledipasvir can be decreased when it is combined with Nelfinavir.	Approved
Lenalidomide	The serum concentration of Lenalidomide can be decreased when it is combined with Nelfinavir.	Approved
Lenvatinib	The metabolism of Lenvatinib can be decreased when combined with Nelfinavir.	Approved
Lercanidipine	The serum concentration of Lercanidipine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Letrozole	The metabolism of Letrozole can be decreased when combined with Nelfinavir.	Approved, Investigational
Leuprolide	Nelfinavir may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levetiracetam	The serum concentration of Levetiracetam can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Levobupivacaine	The serum concentration of Levobupivacaine can be increased when it is combined with Nelfinavir.	Approved
Levocetirizine	The metabolism of Levocetirizine can be decreased when combined with Nelfinavir.	Approved
Levofloxacin	Nelfinavir may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Levomethadyl Acetate	The metabolism of Levomethadyl Acetate can be decreased when combined with Nelfinavir.	Approved
Levomilnacipran	The serum concentration of Levomilnacipran can be increased when it is combined with Nelfinavir.	Approved
Levonorgestrel	The serum concentration of Levonorgestrel can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Levothyroxine	The metabolism of Levothyroxine can be decreased when combined with Nelfinavir.	Approved
Lidocaine	The metabolism of Lidocaine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Linagliptin	The serum concentration of Linagliptin can be decreased when it is combined with Nelfinavir.	Approved
Liothyronine	The serum concentration of Nelfinavir can be decreased when it is combined with Liothyronine.	Approved, Vet Approved
Liotrix	The serum concentration of Nelfinavir can be decreased when it is combined with Liotrix.	Approved
Liraglutide	The therapeutic efficacy of Liraglutide can be decreased when used in combination with Nelfinavir.	Approved
Lisinopril	The serum concentration of Nelfinavir can be increased when it is combined with Lisinopril.	Approved, Investigational
Lisuride	The metabolism of Lisuride can be decreased when combined with Nelfinavir.	Approved
Lomitapide	The serum concentration of Lomitapide can be increased when it is combined with Nelfinavir.	Approved
Loperamide	The metabolism of Loperamide can be decreased when combined with Nelfinavir.	Approved
Lopinavir	The serum concentration of Lopinavir can be decreased when it is combined with Nelfinavir.	Approved
Loratadine	The metabolism of Loratadine can be decreased when combined with Nelfinavir.	Approved
Lorcaserin	The metabolism of Lorcaserin can be decreased when combined with Nelfinavir.	Approved
Losartan	The metabolism of Losartan can be decreased when combined with Nelfinavir.	Approved
Lovastatin	The serum concentration of Lovastatin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Luliconazole	The serum concentration of Nelfinavir can be increased when it is combined with Luliconazole.	Approved
Lumacaftor	The serum concentration of Nelfinavir can be decreased when it is combined with Lumacaftor.	Approved
Lumefantrine	The serum concentration of Lumefantrine can be increased when it is combined with Nelfinavir.	Approved
Lumiracoxib	The metabolism of Lumiracoxib can be decreased when combined with Nelfinavir.	Approved, Investigational
Lurasidone	The serum concentration of Lurasidone can be increased when it is combined with Nelfinavir.	Approved
Lynestrenol	The serum concentration of Lynestrenol can be decreased when it is combined with Nelfinavir.	Investigational
Macitentan	The serum concentration of Macitentan can be increased when it is combined with Nelfinavir.	Approved
Mannitol	The serum concentration of Mannitol can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Maprotiline	The serum concentration of Nelfinavir can be increased when it is combined with Maprotiline.	Approved
Maraviroc	The serum concentration of Maraviroc can be increased when it is combined with Nelfinavir.	Approved, Investigational
ME-609	The serum concentration of ME-609 can be increased when it is combined with Nelfinavir.	Investigational
Mebendazole	The metabolism of Mebendazole can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Medroxyprogesterone acetate	The serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Medrysone	The serum concentration of Medrysone can be increased when it is combined with Nelfinavir.	Approved
Mefloquine	The metabolism of Mefloquine can be decreased when combined with Nelfinavir.	Approved
Megestrol acetate	The serum concentration of Nelfinavir can be increased when it is combined with Megestrol acetate.	Approved, Vet Approved
Melatonin	The metabolism of Melatonin can be decreased when combined with Nelfinavir.	Approved, Nutraceutical, Vet Approved
Meloxicam	The metabolism of Meloxicam can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Mephenytoin	The metabolism of Mephenytoin can be decreased when combined with Nelfinavir.	Investigational, Withdrawn
Meprobamate	The serum concentration of Nelfinavir can be increased when it is combined with Meprobamate.	Approved, Illicit
Mestranol	The serum concentration of Mestranol can be decreased when it is combined with Nelfinavir.	Approved
Metformin	The therapeutic efficacy of Metformin can be decreased when used in combination with Nelfinavir.	Approved
Methadone	The serum concentration of Methadone can be decreased when it is combined with Nelfinavir.	Approved
Methallenestril	The serum concentration of Methallenestril can be decreased when it is combined with Nelfinavir.	Experimental
Methantheline	The serum concentration of Nelfinavir can be decreased when it is combined with Methantheline.	Approved
Methaqualone	The metabolism of Methaqualone can be decreased when combined with Nelfinavir.	Illicit, Withdrawn
Methotrexate	The serum concentration of Methotrexate can be decreased when it is combined with Nelfinavir.	Approved
Methoxsalen	The metabolism of Methoxsalen can be decreased when combined with Nelfinavir.	Approved
Methoxyflurane	The metabolism of Methoxyflurane can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Methsuximide	The metabolism of Methsuximide can be decreased when combined with Nelfinavir.	Approved
Methylphenobarbital	The metabolism of Methylphenobarbital can be decreased when combined with Nelfinavir.	Approved
Methylprednisolone	The serum concentration of Methylprednisolone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Methyltestosterone	The metabolism of Methyltestosterone can be decreased when combined with Nelfinavir.	Approved
Metiamide	The serum concentration of Nelfinavir can be decreased when it is combined with Metiamide.	Experimental
Metoprolol	The serum concentration of Metoprolol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Metronidazole	The metabolism of Metronidazole can be decreased when combined with Nelfinavir.	Approved
Mexiletine	The metabolism of Mexiletine can be decreased when combined with Nelfinavir.	Approved
Mianserin	The metabolism of Mianserin can be decreased when combined with Nelfinavir.	Approved
Mibefradil	The metabolism of Mibefradil can be decreased when combined with Nelfinavir.	Withdrawn
Miconazole	The metabolism of Miconazole can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Midazolam	The serum concentration of Midazolam can be increased when it is combined with Nelfinavir.	Approved, Illicit
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Nelfinavir.	Approved, Investigational
Miglitol	The therapeutic efficacy of Miglitol can be decreased when used in combination with Nelfinavir.	Approved
Miglustat	The therapeutic efficacy of Miglustat can be decreased when used in combination with Nelfinavir.	Approved
Mirabegron	The metabolism of Mirabegron can be decreased when combined with Nelfinavir.	Approved
Mirtazapine	The metabolism of Mirtazapine can be decreased when combined with Nelfinavir.	Approved
Mitiglinide	The therapeutic efficacy of Mitiglinide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Mitomycin	The serum concentration of Nelfinavir can be increased when it is combined with Mitomycin.	Approved
Mitotane	The serum concentration of Nelfinavir can be decreased when it is combined with Mitotane.	Approved
Mitoxantrone	The serum concentration of Mitoxantrone can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Moclobemide	The metabolism of Moclobemide can be decreased when combined with Nelfinavir.	Approved
Modafinil	The metabolism of Modafinil can be decreased when combined with Nelfinavir.	Approved, Investigational
Mometasone	The serum concentration of Mometasone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Montelukast	The metabolism of Montelukast can be decreased when combined with Nelfinavir.	Approved
Morphine	The metabolism of Morphine can be decreased when combined with Nelfinavir.	Approved, Investigational
Moxifloxacin	Nelfinavir may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The metabolism of Mycophenolate mofetil can be decreased when combined with Nelfinavir.	Approved, Investigational
Nadolol	The serum concentration of Nadolol can be decreased when it is combined with Nelfinavir.	Approved
Nafcillin	The serum concentration of Nelfinavir can be decreased when it is combined with Nafcillin.	Approved
Naloxegol	The serum concentration of Naloxegol can be increased when it is combined with Nelfinavir.	Approved
Naloxone	The metabolism of Naloxone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Naltrexone	The serum concentration of Nelfinavir can be increased when it is combined with Naltrexone.	Approved, Investigational, Vet Approved
Naringenin	The serum concentration of Nelfinavir can be increased when it is combined with Naringenin.	Experimental
Nateglinide	The metabolism of Nateglinide can be decreased when combined with Nelfinavir.	Approved, Investigational
NCX 1022	The serum concentration of NCX 1022 can be increased when it is combined with Nelfinavir.	Investigational
Nefazodone	The serum concentration of Nefazodone can be increased when it is combined with Nelfinavir.	Approved, Withdrawn
Neostigmine	The serum concentration of Nelfinavir can be increased when it is combined with Neostigmine.	Approved, Vet Approved
Netupitant	The serum concentration of Nelfinavir can be increased when it is combined with Netupitant.	Approved
Nevirapine	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Nevirapine resulting in a loss in efficacy.	Approved
Nicardipine	The metabolism of Nicardipine can be decreased when combined with Nelfinavir.	Approved
Nicotine	The metabolism of Nicotine can be decreased when combined with Nelfinavir.	Approved
Nifedipine	The metabolism of Nifedipine can be decreased when combined with Nelfinavir.	Approved
Nilotinib	The serum concentration of Nilotinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Nilutamide	The metabolism of Nilutamide can be decreased when combined with Nelfinavir.	Approved
Nilvadipine	The metabolism of Nilvadipine can be decreased when combined with Nelfinavir.	Approved
Nimodipine	The serum concentration of Nimodipine can be increased when it is combined with Nelfinavir.	Approved
Nintedanib	The serum concentration of Nintedanib can be increased when it is combined with Nelfinavir.	Approved
Nisoldipine	The serum concentration of Nisoldipine can be increased when it is combined with Nelfinavir.	Approved
Nitrazepam	The metabolism of Nitrazepam can be decreased when combined with Nelfinavir.	Approved
Nitrendipine	The metabolism of Nitrendipine can be decreased when combined with Nelfinavir.	Approved
Nizatidine	The serum concentration of Nelfinavir can be decreased when it is combined with Nizatidine.	Approved
Norelgestromin	The serum concentration of Norelgestromin can be decreased when it is combined with Nelfinavir.	Approved
Norethisterone	The metabolism of Norethisterone can be decreased when combined with Nelfinavir.	Approved
Norgestimate	The serum concentration of Norgestimate can be decreased when it is combined with Nelfinavir.	Approved
Norgestrel	The serum concentration of Norgestrel can be decreased when it is combined with Nelfinavir.	Approved
Nortriptyline	The metabolism of Nortriptyline can be decreased when combined with Nelfinavir.	Approved
Ofloxacin	Nelfinavir may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olanzapine	The serum concentration of Nelfinavir can be decreased when it is combined with Olanzapine.	Approved, Investigational
Olaparib	The serum concentration of Olaparib can be increased when it is combined with Nelfinavir.	Approved
Oleoyl-estrone	The serum concentration of Oleoyl estrone can be increased when it is combined with Nelfinavir.	Investigational
Olopatadine	The metabolism of Olopatadine can be decreased when combined with Nelfinavir.	Approved
Ombitasvir	The serum concentration of Ombitasvir can be decreased when it is combined with Nelfinavir.	Approved
Omeprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Omeprazole resulting in a loss in efficacy.	Approved, Investigational, Vet Approved
Ondansetron	The metabolism of Ondansetron can be decreased when combined with Nelfinavir.	Approved
Opipramol	The serum concentration of Opipramol can be increased when it is combined with Nelfinavir.	Investigational
Orphenadrine	The metabolism of Orphenadrine can be decreased when combined with Nelfinavir.	Approved
Osimertinib	The serum concentration of Osimertinib can be increased when it is combined with Nelfinavir.	Approved
Ospemifene	The serum concentration of Ospemifene can be increased when it is combined with Nelfinavir.	Approved
Oxazepam	The metabolism of Oxazepam can be decreased when combined with Nelfinavir.	Approved
Oxiconazole	The metabolism of Oxiconazole can be decreased when combined with Nelfinavir.	Approved
Oxybutynin	The serum concentration of Oxybutynin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Oxycodone	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	The metabolism of Oxymorphone can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
P-Nitrophenol	The serum concentration of Nelfinavir can be increased when it is combined with P-Nitrophenol.	Experimental
Paclitaxel	The metabolism of Paclitaxel can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Palbociclib	The serum concentration of Palbociclib can be increased when it is combined with Nelfinavir.	Approved
Paliperidone	Nelfinavir may increase the QTc-prolonging activities of Paliperidone.	Approved
Palmitic Acid	The serum concentration of Nelfinavir can be increased when it is combined with Palmitic Acid.	Experimental
Palonosetron	The metabolism of Palonosetron can be decreased when combined with Nelfinavir.	Approved, Investigational
Panobinostat	The serum concentration of Panobinostat can be increased when it is combined with Nelfinavir.	Approved, Investigational
Pantoprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Pantoprazole resulting in a loss in efficacy.	Approved
Paramethadione	The metabolism of Paramethadione can be decreased when combined with Nelfinavir.	Approved
Paramethasone	The metabolism of Paramethasone can be decreased when combined with Nelfinavir.	Approved
Parecoxib	The serum concentration of Parecoxib can be increased when it is combined with Nelfinavir.	Approved
Paricalcitol	The serum concentration of Paricalcitol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Paritaprevir	The metabolism of Paritaprevir can be decreased when combined with Nelfinavir.	Approved
Paroxetine	The serum concentration of Nelfinavir can be increased when it is combined with Paroxetine.	Approved, Investigational
Pazopanib	The serum concentration of Pazopanib can be increased when it is combined with Nelfinavir.	Approved
Pentamidine	The metabolism of Pentamidine can be decreased when combined with Nelfinavir.	Approved
Pentobarbital	The metabolism of Nelfinavir can be increased when combined with Pentobarbital.	Approved, Vet Approved
Perampanel	The metabolism of Perampanel can be decreased when combined with Nelfinavir.	Approved
Perflutren	Nelfinavir may increase the QTc-prolonging activities of Perflutren.	Approved
Pergolide	The metabolism of Pergolide can be decreased when combined with Nelfinavir.	Approved, Vet Approved, Withdrawn
Perhexiline	The metabolism of Perhexiline can be decreased when combined with Nelfinavir.	Approved
Perindopril	The serum concentration of Nelfinavir can be increased when it is combined with Perindopril.	Approved
Permethrin	The metabolism of Permethrin can be decreased when combined with Nelfinavir.	Approved, Investigational
Perphenazine	The metabolism of Perphenazine can be decreased when combined with Nelfinavir.	Approved
Pethidine	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Pethidine.	Approved
Phenacetin	The metabolism of Phenacetin can be decreased when combined with Nelfinavir.	Withdrawn
Phenformin	The therapeutic efficacy of Phenformin can be decreased when used in combination with Nelfinavir.	Approved, Withdrawn
Phenobarbital	The metabolism of Nelfinavir can be increased when combined with Phenobarbital.	Approved
Phenoxybenzamine	The metabolism of Phenoxybenzamine can be decreased when combined with Nelfinavir.	Approved
Phenprocoumon	The metabolism of Phenprocoumon can be decreased when combined with Nelfinavir.	Approved
Phenytoin	The serum concentration of Phenytoin can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Pilocarpine	The metabolism of Pilocarpine can be decreased when combined with Nelfinavir.	Approved
Pimecrolimus	The metabolism of Pimecrolimus can be decreased when combined with Nelfinavir.	Approved, Investigational
Pimozide	The serum concentration of Pimozide can be increased when it is combined with Nelfinavir.	Approved
Pioglitazone	The metabolism of Pioglitazone can be decreased when combined with Nelfinavir.	Approved, Investigational
Pipotiazine	The metabolism of Pipotiazine can be decreased when combined with Nelfinavir.	Approved
Pitavastatin	The serum concentration of Pitavastatin can be decreased when it is combined with Nelfinavir.	Approved
Platelet Activating Factor	The serum concentration of Nelfinavir can be decreased when it is combined with Platelet Activating Factor.	Experimental
Podofilox	The metabolism of Podofilox can be decreased when combined with Nelfinavir.	Approved
Pomalidomide	The metabolism of Pomalidomide can be decreased when combined with Nelfinavir.	Approved
Ponatinib	The serum concentration of Ponatinib can be increased when it is combined with Nelfinavir.	Approved
Posaconazole	The metabolism of Posaconazole can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Pramlintide	The therapeutic efficacy of Pramlintide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Pranlukast	The serum concentration of Pranlukast can be increased when it is combined with Nelfinavir.	Approved
Prasterone	The metabolism of Prasterone can be decreased when combined with Nelfinavir.	Approved, Nutraceutical
Prasterone sulfate	The serum concentration of dehydroepiandrosterone sulfate can be increased when it is combined with Nelfinavir.	Investigational
Prasugrel	The serum concentration of the active metabolites of Prasugrel can be reduced when Prasugrel is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Pravastatin	The serum concentration of Pravastatin can be decreased when it is combined with Nelfinavir.	Approved
Prazepam	The metabolism of Prazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Praziquantel	The metabolism of Praziquantel can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Prazosin	The serum concentration of Prazosin can be decreased when it is combined with Nelfinavir.	Approved
Prednicarbate	The serum concentration of Prednicarbate can be increased when it is combined with Nelfinavir.	Approved
Prednisolone	The metabolism of Prednisolone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Prednisolone	The serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Prednisone	The serum concentration of Prednisone can be increased when it is combined with Nelfinavir.	Approved, Vet Approved
Pregnenolone	The serum concentration of Pregnenolone can be increased when it is combined with Nelfinavir.	Experimental
Primaquine	The metabolism of Primaquine can be decreased when combined with Nelfinavir.	Approved
Primidone	The metabolism of Nelfinavir can be increased when combined with Primidone.	Approved, Vet Approved
Probenecid	The serum concentration of Nelfinavir can be increased when it is combined with Probenecid.	Approved
Procainamide	Nelfinavir may increase the QTc-prolonging activities of Procainamide.	Approved
Prochlorperazine	The metabolism of Prochlorperazine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Progesterone	The metabolism of Progesterone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Proguanil	The metabolism of Proguanil can be decreased when combined with Nelfinavir.	Approved
Promazine	The metabolism of Promazine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Promethazine	The serum concentration of Nelfinavir can be increased when it is combined with Promethazine.	Approved
Propafenone	The serum concentration of Propafenone can be increased when it is combined with Nelfinavir.	Approved
Propofol	The metabolism of Propofol can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Propranolol	The metabolism of Propranolol can be decreased when combined with Nelfinavir.	Approved, Investigational
Protriptyline	The serum concentration of Protriptyline can be increased when it is combined with Nelfinavir.	Approved
Prucalopride	The serum concentration of Prucalopride can be increased when it is combined with Nelfinavir.	Approved
Pyrazinamide	The metabolism of Pyrazinamide can be decreased when combined with Nelfinavir.	Approved
Quazepam	The metabolism of Quazepam can be decreased when combined with Nelfinavir.	Approved, Illicit
Quercetin	The serum concentration of Nelfinavir can be increased when it is combined with Quercetin.	Experimental
Quetiapine	The serum concentration of Quetiapine can be increased when it is combined with Nelfinavir.	Approved
Quinacrine	The metabolism of Quinacrine can be decreased when combined with Nelfinavir.	Approved
Quinidine	The serum concentration of Quinidine can be increased when it is combined with Nelfinavir.	Approved
Quinine	The metabolism of Quinine can be decreased when combined with Nelfinavir.	Approved
Rabeprazole	The serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Rabeprazole resulting in a loss in efficacy.	Approved, Investigational
Raloxifene	The metabolism of Raloxifene can be decreased when combined with Nelfinavir.	Approved, Investigational
Ramelteon	The serum concentration of Ramelteon can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ranitidine	The serum concentration of Nelfinavir can be decreased when it is combined with Ranitidine.	Approved
Ranolazine	The serum concentration of Ranolazine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Reboxetine	The metabolism of Reboxetine can be decreased when combined with Nelfinavir.	Approved, Investigational
Regorafenib	The serum concentration of Regorafenib can be increased when it is combined with Nelfinavir.	Approved
Repaglinide	The serum concentration of Repaglinide can be increased when it is combined with Nelfinavir.	Approved, Investigational
Reserpine	The serum concentration of Reserpine can be decreased when it is combined with Nelfinavir.	Approved
Retapamulin	The serum concentration of Retapamulin can be increased when it is combined with Nelfinavir.	Approved
Rifabutin	The serum concentration of the active metabolites of Rifabutin can be increased when Rifabutin is used in combination with Nelfinavir.	Approved
Rifampicin	The serum concentration of Nelfinavir can be decreased when it is combined with Rifampicin.	Approved
Rifapentine	The metabolism of Nelfinavir can be increased when combined with Rifapentine.	Approved
Rifaximin	The serum concentration of Rifaximin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Rilpivirine	The serum concentration of Rilpivirine can be increased when it is combined with Nelfinavir.	Approved
Rimexolone	The serum concentration of Rimexolone can be increased when it is combined with Nelfinavir.	Approved
Rimonabant	The metabolism of Rimonabant can be decreased when combined with Nelfinavir.	Approved, Investigational
Riociguat	The serum concentration of Riociguat can be increased when it is combined with Nelfinavir.	Approved
Risperidone	The metabolism of Risperidone can be decreased when combined with Nelfinavir.	Approved, Investigational
Ritonavir	The metabolism of Ritonavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Rivaroxaban	The metabolism of Rivaroxaban can be decreased when combined with Nelfinavir.	Approved
Rofecoxib	The metabolism of Rofecoxib can be decreased when combined with Nelfinavir.	Investigational, Withdrawn
Rolapitant	The metabolism of Rolapitant can be decreased when combined with Nelfinavir.	Approved
Romidepsin	The serum concentration of Romidepsin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Ropinirole	The metabolism of Ropinirole can be decreased when combined with Nelfinavir.	Approved, Investigational
Ropivacaine	The metabolism of Ropivacaine can be decreased when combined with Nelfinavir.	Approved
Rosiglitazone	The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Rosuvastatin	The serum concentration of Rosuvastatin can be increased when it is combined with Nelfinavir.	Approved
Rotigotine	The metabolism of Rotigotine can be decreased when combined with Nelfinavir.	Approved
Roxatidine acetate	The serum concentration of Nelfinavir can be decreased when it is combined with Roxatidine acetate.	Approved
Roxithromycin	The metabolism of Roxithromycin can be decreased when combined with Nelfinavir.	Approved, Withdrawn
Ruxolitinib	The serum concentration of Ruxolitinib can be increased when it is combined with Nelfinavir.	Approved
Salicylic acid	The serum concentration of Salicylic acid can be decreased when it is combined with Nelfinavir.	Approved, Vet Approved
Salmeterol	The serum concentration of Salmeterol can be increased when it is combined with Nelfinavir.	Approved
Saquinavir	The metabolism of Saquinavir can be decreased when combined with Nelfinavir.	Approved, Investigational
Saxagliptin	The serum concentration of Saxagliptin can be increased when it is combined with Nelfinavir.	Approved
Scopolamine	The serum concentration of Nelfinavir can be increased when it is combined with Scopolamine.	Approved
Selegiline	The metabolism of Selegiline can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Selexipag	The metabolism of Selexipag can be decreased when combined with Nelfinavir.	Approved
Sertindole	The metabolism of Sertindole can be decreased when combined with Nelfinavir.	Approved, Withdrawn
Sertraline	The metabolism of Sertraline can be decreased when combined with Nelfinavir.	Approved
Sevoflurane	The metabolism of Sevoflurane can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Sibutramine	The metabolism of Sibutramine can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational, Withdrawn
Sildenafil	The serum concentration of Sildenafil can be increased when it is combined with Nelfinavir.	Approved, Investigational
Silodosin	The serum concentration of Silodosin can be increased when it is combined with Nelfinavir.	Approved
Siltuximab	The serum concentration of Nelfinavir can be decreased when it is combined with Siltuximab.	Approved
Simeprevir	The serum concentration of Simeprevir can be increased when it is combined with Nelfinavir.	Approved
Simvastatin	The serum concentration of Simvastatin can be increased when it is combined with Nelfinavir.	Approved
Sirolimus	The serum concentration of Sirolimus can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sitagliptin	The metabolism of Sitagliptin can be decreased when combined with Nelfinavir.	Approved, Investigational
Sofosbuvir	The serum concentration of Sofosbuvir can be decreased when it is combined with Nelfinavir.	Approved
Solifenacin	The metabolism of Solifenacin can be decreased when combined with Nelfinavir.	Approved
Sonidegib	The serum concentration of Sonidegib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sorafenib	The serum concentration of Sorafenib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Sotalol	Nelfinavir may increase the QTc-prolonging activities of Sotalol.	Approved
Sparfloxacin	The serum concentration of Sparfloxacin can be decreased when it is combined with Nelfinavir.	Approved
Sphingosine	The serum concentration of Sphingosine can be decreased when it is combined with Nelfinavir.	Experimental
Spiramycin	The metabolism of Spiramycin can be decreased when combined with Nelfinavir.	Approved
Spironolactone	The serum concentration of Nelfinavir can be increased when it is combined with Spironolactone.	Approved
St. John's Wort	The metabolism of Nelfinavir can be increased when combined with St. John's Wort.	Nutraceutical
Staurosporine	The serum concentration of Nelfinavir can be increased when it is combined with Staurosporine.	Experimental
Stiripentol	The serum concentration of Nelfinavir can be increased when it is combined with Stiripentol.	Approved
Streptozocin	The serum concentration of Nelfinavir can be decreased when it is combined with Streptozocin.	Approved
Sufentanil	The metabolism of Sufentanil can be decreased when combined with Nelfinavir.	Approved, Investigational
Sulfadiazine	The metabolism of Sulfadiazine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Sulfamethoxazole	The metabolism of Sulfamethoxazole can be decreased when combined with Nelfinavir.	Approved
Sulfinpyrazone	The metabolism of Sulfinpyrazone can be decreased when combined with Nelfinavir.	Approved
Sulfisoxazole	Nelfinavir may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulodexide	The therapeutic efficacy of Sulodexide can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Sumatriptan	The serum concentration of Nelfinavir can be increased when it is combined with Sumatriptan.	Approved, Investigational
Sunitinib	The metabolism of Sunitinib can be decreased when combined with Nelfinavir.	Approved, Investigational
Suvorexant	The serum concentration of Suvorexant can be increased when it is combined with Nelfinavir.	Approved
Synthetic Conjugated Estrogens, A	The metabolism of Synthetic Conjugated Estrogens, A can be decreased when combined with Nelfinavir.	Approved
Synthetic Conjugated Estrogens, B	The metabolism of Synthetic Conjugated Estrogens, B can be decreased when combined with Nelfinavir.	Approved
Tacrine	The serum concentration of Nelfinavir can be increased when it is combined with Tacrine.	Withdrawn
Tacrolimus	The metabolism of Tacrolimus can be decreased when combined with Nelfinavir.	Approved, Investigational
Tadalafil	The serum concentration of Tadalafil can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tamoxifen	The metabolism of Tamoxifen can be decreased when combined with Nelfinavir.	Approved
Tamsulosin	The serum concentration of Tamsulosin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tapentadol	The metabolism of Tapentadol can be decreased when combined with Nelfinavir.	Approved
Tasimelteon	The serum concentration of Tasimelteon can be increased when it is combined with Nelfinavir.	Approved
Tasosartan	The metabolism of Tasosartan can be decreased when combined with Nelfinavir.	Approved
Taurocholic Acid	The serum concentration of Taurocholic Acid can be decreased when it is combined with Nelfinavir.	Experimental
Technetium Tc-99m sestamibi	The serum concentration of Technetium Tc-99m sestamibi can be decreased when it is combined with Nelfinavir.	Approved
Telaprevir	The metabolism of Telaprevir can be decreased when combined with Nelfinavir.	Withdrawn
Telavancin	Nelfinavir may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	The metabolism of Telithromycin can be decreased when combined with Nelfinavir.	Approved
Telmisartan	The serum concentration of Nelfinavir can be increased when it is combined with Telmisartan.	Approved, Investigational
Temazepam	The metabolism of Temazepam can be decreased when combined with Nelfinavir.	Approved
Temsirolimus	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Temsirolimus.	Approved
Teniposide	The metabolism of Teniposide can be decreased when combined with Nelfinavir.	Approved
Terazosin	The serum concentration of Nelfinavir can be increased when it is combined with Terazosin.	Approved
Terbinafine	The metabolism of Terbinafine can be decreased when combined with Nelfinavir.	Approved, Investigational, Vet Approved
Terfenadine	The serum concentration of Terfenadine can be increased when it is combined with Nelfinavir.	Withdrawn
Tesmilifene	The metabolism of Tesmilifene can be decreased when combined with Nelfinavir.	Investigational
Testosterone	The metabolism of Testosterone can be decreased when combined with Nelfinavir.	Approved, Investigational
Tetrabenazine	Nelfinavir may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Tetracycline	The metabolism of Tetracycline can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Thalidomide	The metabolism of Thalidomide can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Theophylline	The metabolism of Theophylline can be decreased when combined with Nelfinavir.	Approved
Thioridazine	The serum concentration of Thioridazine can be increased when it is combined with Nelfinavir.	Withdrawn
Thiotepa	The metabolism of Thiotepa can be decreased when combined with Nelfinavir.	Approved
Tiagabine	The metabolism of Tiagabine can be decreased when combined with Nelfinavir.	Approved
Tianeptine	The serum concentration of Tianeptine can be increased when it is combined with Nelfinavir.	Approved
Ticagrelor	The serum concentration of the active metabolites of Ticagrelor can be reduced when Ticagrelor is used in combination with Nelfinavir resulting in a loss in efficacy.	Approved
Ticlopidine	The metabolism of Ticlopidine can be decreased when combined with Nelfinavir.	Approved
Timolol	The serum concentration of Timolol can be decreased when it is combined with Nelfinavir.	Approved
Tinidazole	The metabolism of Tinidazole can be decreased when combined with Nelfinavir.	Approved, Investigational
Tiotropium	The metabolism of Tiotropium can be decreased when combined with Nelfinavir.	Approved
Tipranavir	The serum concentration of Nelfinavir can be decreased when it is combined with Tipranavir.	Approved, Investigational
Tixocortol	The serum concentration of Tixocortol can be increased when it is combined with Nelfinavir.	Approved
Tizanidine	The serum concentration of Tizanidine can be increased when it is combined with Nelfinavir.	Approved
Tocilizumab	The serum concentration of Nelfinavir can be decreased when it is combined with Tocilizumab.	Approved
Tofacitinib	The serum concentration of Tofacitinib can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tolazamide	The therapeutic efficacy of Tolazamide can be decreased when used in combination with Nelfinavir.	Approved
Tolbutamide	The metabolism of Tolbutamide can be decreased when combined with Nelfinavir.	Approved
Tolterodine	The serum concentration of Tolterodine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tolvaptan	The serum concentration of Tolvaptan can be increased when it is combined with Nelfinavir.	Approved
Topiramate	The metabolism of Nelfinavir can be decreased when combined with Topiramate.	Approved
Topotecan	The serum concentration of Topotecan can be increased when it is combined with Nelfinavir.	Approved, Investigational
Toremifene	The risk or severity of adverse effects can be increased when Nelfinavir is combined with Toremifene.	Approved, Investigational
Trabectedin	The serum concentration of Trabectedin can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tramadol	The serum concentration of Tramadol can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tranylcypromine	The metabolism of Nelfinavir can be decreased when combined with Tranylcypromine.	Approved
Trastuzumab emtansine	The serum concentration of the active metabolites of Trastuzumab emtansine can be increased when Trastuzumab emtansine is used in combination with Nelfinavir.	Approved
Trazodone	The serum concentration of Trazodone can be increased when it is combined with Nelfinavir.	Approved, Investigational
Tretinoin	The metabolism of Tretinoin can be decreased when combined with Nelfinavir.	Approved, Investigational, Nutraceutical
Triamcinolone	The metabolism of Triamcinolone can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Triazolam	The serum concentration of Triazolam can be increased when it is combined with Nelfinavir.	Approved
Trifluoperazine	The serum concentration of Nelfinavir can be increased when it is combined with Trifluoperazine.	Approved
Triflupromazine	The serum concentration of Nelfinavir can be increased when it is combined with Triflupromazine.	Approved, Vet Approved
Trimethadione	The metabolism of Trimethadione can be decreased when combined with Nelfinavir.	Approved
Trimethoprim	The metabolism of Trimethoprim can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Trimipramine	The metabolism of Trimipramine can be decreased when combined with Nelfinavir.	Approved
Troglitazone	The metabolism of Troglitazone can be decreased when combined with Nelfinavir.	Withdrawn
Udenafil	The metabolism of Udenafil can be decreased when combined with Nelfinavir.	Approved, Investigational
Ulipristal	The serum concentration of Ulipristal can be increased when it is combined with Nelfinavir.	Approved
Umeclidinium	The serum concentration of Umeclidinium can be decreased when it is combined with Nelfinavir.	Approved
Valdecoxib	The metabolism of Valdecoxib can be decreased when combined with Nelfinavir.	Investigational, Withdrawn
Valproic Acid	The serum concentration of Valproic Acid can be decreased when it is combined with Nelfinavir.	Approved, Investigational
Vandetanib	The metabolism of Vandetanib can be decreased when combined with Nelfinavir.	Approved
Vanoxerine	The metabolism of Vanoxerine can be decreased when combined with Nelfinavir.	Investigational
Vardenafil	The serum concentration of Vardenafil can be increased when it is combined with Nelfinavir.	Approved
Vecuronium	The serum concentration of Vecuronium can be decreased when it is combined with Nelfinavir.	Approved
Vemurafenib	The serum concentration of Vemurafenib can be increased when it is combined with Nelfinavir.	Approved
Venetoclax	The metabolism of Venetoclax can be decreased when combined with Nelfinavir.	Approved
Venlafaxine	The metabolism of Venlafaxine can be decreased when combined with Nelfinavir.	Approved
Verapamil	The metabolism of Verapamil can be decreased when combined with Nelfinavir.	Approved
Vilanterol	The metabolism of Vilanterol can be decreased when combined with Nelfinavir.	Approved
Vilazodone	The serum concentration of Vilazodone can be increased when it is combined with Nelfinavir.	Approved
Vildagliptin	The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Vinblastine	The metabolism of Vinblastine can be decreased when combined with Nelfinavir.	Approved
Vincristine	The serum concentration of Vincristine can be increased when it is combined with Nelfinavir.	Approved, Investigational
Vincristine	The metabolism of Vincristine can be decreased when combined with Nelfinavir.	Approved, Investigational
Vindesine	The serum concentration of Vindesine can be increased when it is combined with Nelfinavir.	Approved
Vinorelbine	The metabolism of Vinorelbine can be decreased when combined with Nelfinavir.	Approved, Investigational
Vismodegib	The metabolism of Vismodegib can be decreased when combined with Nelfinavir.	Approved
Voglibose	The therapeutic efficacy of Voglibose can be decreased when used in combination with Nelfinavir.	Approved, Investigational
Vorapaxar	The serum concentration of Vorapaxar can be increased when it is combined with Nelfinavir.	Approved
Voriconazole	The serum concentration of Nelfinavir can be increased when it is combined with Voriconazole.	Approved, Investigational
Vortioxetine	The metabolism of Vortioxetine can be decreased when combined with Nelfinavir.	Approved
Warfarin	The serum concentration of Warfarin can be decreased when it is combined with Nelfinavir.	Approved
Yohimbine	The metabolism of Yohimbine can be decreased when combined with Nelfinavir.	Approved, Vet Approved
Zafirlukast	The metabolism of Zafirlukast can be decreased when combined with Nelfinavir.	Approved, Investigational
Zalcitabine	The metabolism of Zalcitabine can be decreased when combined with Nelfinavir.	Approved
Zaleplon	The metabolism of Zaleplon can be decreased when combined with Nelfinavir.	Approved, Illicit, Investigational
Zidovudine	The serum concentration of Zidovudine can be decreased when it is combined with Nelfinavir.	Approved
Zileuton	The metabolism of Zileuton can be decreased when combined with Nelfinavir.	Approved, Investigational, Withdrawn
Zimelidine	The serum concentration of Nelfinavir can be increased when it is combined with Zimelidine.	Withdrawn
Ziprasidone	The metabolism of Ziprasidone can be decreased when combined with Nelfinavir.	Approved
Zolpidem	The metabolism of Zolpidem can be decreased when combined with Nelfinavir.	Approved
Zomepirac	The metabolism of Zomepirac can be decreased when combined with Nelfinavir.	Withdrawn
Zonisamide	The metabolism of Zonisamide can be decreased when combined with Nelfinavir.	Approved, Investigational
Zopiclone	The serum concentration of Zopiclone can be increased when it is combined with Nelfinavir.	Approved
Zuclopenthixol	The serum concentration of Zuclopenthixol can be increased when it is combined with Nelfinavir.	Approved, Investigational

Food Interactions

Food significantly increases absorption (2 to 3 times).
Take with food.

References

Synthesis Reference

US5461154

General References

Kaldor SW, Kalish VJ, Davies JF 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH: Viracept (nelfinavir mesylate, AG1343): a potent, orally bioavailable inhibitor of HIV-1 protease. J Med Chem. 1997 Nov 21;40(24):3979-85. [PubMed:9397180 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14365
KEGG Drug	D08259
KEGG Compound	C07257
PubChem Compound	64143
PubChem Substance	46507719
ChemSpider	57718
BindingDB	518
ChEBI	7496
ChEMBL	CHEMBL584
Therapeutic Targets Database	DAP000705
PharmGKB	PA450606
HET	1UN
Drug Product Database	11789
RxList	http://www.rxlist.com/cgi/generic2/nelfin.htm
Drugs.com	http://www.drugs.com/cdi/nelfinavir.html
PDRhealth	http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/vir1483.shtml
Wikipedia	Nelfinavir

ATC Codes

J05AE04 — Nelfinavir

AHFS Codes

08:18.08.08

PDB Entries

1ODW

FDA label

Download (294 KB)

MSDS

Download (56.6 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
0	Terminated	Treatment	Castleman's Disease / EBV / Kaposi s Sarcoma (KS) / Lymphoma, Hodgkins / Malignant Neoplasm of Nasopharynx / Malignant Neoplasm of Stomach / Non-Hodgkin's Lymphoma (NHL)	1
1	Active Not Recruiting	Not Available	Gliomas	1
1	Active Not Recruiting	Treatment	Adenocarcinoma of the Pancreas / Stage III Pancreatic Cancer	1
1	Active Not Recruiting	Treatment	Brain and Central Nervous System Tumors	1
1	Active Not Recruiting	Treatment	Cancer, Ovarian / Carcinoid tumour of the gastrointestinal tract / Colorectal Cancers / Head and Neck Carcinoma / Islet Cell Tumor / Lung Cancers / Metastatic Cancers / Neuroendocrine Carcinoma of the Skin / Pheochromocytomas / Sarcomas / Unspecified Adult Solid Tumor, Protocol Specific	1
1	Active Not Recruiting	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
1	Completed	Treatment	Cancers / Renal Cell Adenocarcinoma	1
1	Completed	Treatment	Cervical Cancers	1
1	Completed	Treatment	Glioblastomas	1
1	Completed	Treatment	HIV Seronegativity / Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
1	Completed	Treatment	Healthy Volunteers	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	12
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
1	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
1	Completed	Treatment	Immune Response	1
1	Completed	Treatment	Leukemias / Malignant Lymphomas / Mature T-cell and Nk-cell Neoplasms / Multiple Myeloma and Plasma Cell Neoplasm	1
1	Completed	Treatment	Sepsis	1
1	Completed	Treatment	Tumors, Solid	1
1	Recruiting	Treatment	Uterine Cervix Cancer	1
1	Terminated	Prevention	Cardiopulmonary Bypass	1
1	Terminated	Treatment	Neoplasms, Pancreatic	1
1, 2	Active Not Recruiting	Treatment	Lung Cancers	1
1, 2	Active Not Recruiting	Treatment	Multiple Myeloma (MM)	1
1, 2	Completed	Treatment	Carcinoma, Colorectal / Colorectal Cancers / Colorectal Tumors / Neoplasms, Colorectal	1
1, 2	Recruiting	Treatment	Pancreatic Neoplasms (Locally Advanced Non-metastatic)	1
1, 2	Terminated	Treatment	Adult Liposarcoma / Recurrent Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma	1
1, 2	Withdrawn	Treatment	Lung Cancers	1
2	Active Not Recruiting	Treatment	Carcinoma, Adenoid Cystic / Neoplasms, Head and Neck	1
2	Active Not Recruiting	Treatment	Oligometastases	1
2	Active Not Recruiting	Treatment	Plasma Cell Myeloma	1
2	Completed	Treatment	Cytomegalovirus Retinitis / Human Immunodeficiency Virus (HIV) Infections	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	16
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare	1
2	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Kaposi s Sarcoma (KS)	1
2	Completed	Treatment	Sarcomas	1
2	Recruiting	Diagnostic	Stage III, IVa, or IVb Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Larynx, or Hypopharynx	1
2	Recruiting	Treatment	Adenocarcinoma of the Pancreas / Resectable Pancreatic Cancers / Resectable Pancreatic Carcinoma / Stage I Pancreatic Cancer / Stage IA Pancreatic Cancer / Stage IB Pancreatic Cancer / Stage II Pancreatic Cancer / Stage IIA Pancreatic Cancer / Stage IIB Pancreatic Cancer / Stage III Pancreatic Cancer	1
2	Recruiting	Treatment	Cervical Dysplasia	1
2	Recruiting	Treatment	Metastatic Renal Cell Cancer / Recurrent Melanoma / Recurrent Non-Small Cell Lung Carcinoma / Renal Cell Carcinoma Recurrent / Stage IV Non-Small Cell Lung Cancer / Stage IV Renal Cell Cancer / Stage IV Skin Melanoma	1
2	Recruiting	Treatment	Recurrent Kaposi's Sarcoma / Skin Kaposi Sarcoma	1
2	Recruiting	Treatment	Systemic Lupus Erythematosus (SLE)	1
2	Suspended	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
2	Terminated	Treatment	Non-Small-Cell Lung Carcinoma (NSCLC)	1
2	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2	Withdrawn	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
2, 3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Prevention	Disease Transmission, Vertical / Human Immunodeficiency Virus (HIV) Infections / Vertical Human Immunodeficiency Virus Transmission	1
3	Completed	Treatment	AIDS-Associated Nephropathy / Human Immunodeficiency Virus (HIV) Infections	1
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	9
3	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Pregnancy	1
3	Terminated	Prevention	Diarrhea	1
3	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
3	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	3
4	Completed	Diagnostic	Cardiovascular Disease (CVD) / HIV-Associated Lipodystrophy Syndrome	1
4	Completed	Diagnostic	Human Immunodeficiency Virus (HIV) Infections / Lipodystrophies	1
4	Completed	Treatment	Healthy Volunteers	2
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	2
4	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Tuberculosis	1
4	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections	20
Not Available	Completed	Treatment	Human Immunodeficiency Virus (HIV) Infections / Infection, Mycobacterium Avium-Intracellulare	1
Not Available	Terminated	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
Not Available	Unknown Status	Treatment	Human Immunodeficiency Virus (HIV) Infections	1

Pharmacoeconomics

Manufacturers

Agouron pharmaceuticals inc

Packagers

Agouron Pharmaceuticals Inc.
A-S Medication Solutions LLC
Cardinal Health
Dept Health Central Pharmacy
Dispensing Solutions
Goedecke GmbH
H.J. Harkins Co. Inc.
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Patheon Inc.
PD-Rx Pharmaceuticals Inc.
Pfizer Inc.
Physicians Total Care Inc.
Quality Care
Remedy Repack
St Mary's Medical Park Pharmacy
Watson Pharmaceuticals

Dosage forms

Form	Route	Strength
Powder	Oral	50 mg/g
Tablet	Oral	625 mg
Tablet, film coated	Oral	250 mg/1
Tablet, film coated	Oral	625 mg/1
Tablet	Oral	250 mg
Powder	Oral	50 mg

Prices

Unit description	Cost	Unit
Viracept 625 mg tablet	11.24USD	tablet
Viracept 250 mg tablet	3.46USD	tablet
Viracept 50 mg/gm Powder	0.54USD	gm

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2173328	No	1999-08-31	2014-10-07	Canada
US5484926	No	1994-04-07	2014-04-07	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	349.84 °C	Not Available
water solubility	Slightly soluble	Not Available
logP	6	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.00191 mg/mL	ALOGPS
logP	4.61	ALOGPS
logP	4.72	ChemAxon
logS	-5.5	ALOGPS
pKa (Strongest Acidic)	9.32	ChemAxon
pKa (Strongest Basic)	8.18	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	5	ChemAxon
Hydrogen Donor Count	4	ChemAxon
Polar Surface Area	101.9 Å²	ChemAxon
Rotatable Bond Count	10	ChemAxon
Refractivity	162.67 m³·mol^-1	ChemAxon
Polarizability	63.8 Å³	ChemAxon
Number of Rings	4	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	No	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	Yes	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.7472
Blood Brain Barrier	-	0.9659
Caco-2 permeable	-	0.7148
P-glycoprotein substrate	Substrate	0.9332
P-glycoprotein inhibitor I	Inhibitor	0.8121
P-glycoprotein inhibitor II	Inhibitor	0.7572
Renal organic cation transporter	Non-inhibitor	0.8178
CYP450 2C9 substrate	Non-substrate	0.7482
CYP450 2D6 substrate	Substrate	0.8918
CYP450 3A4 substrate	Substrate	0.7408
CYP450 1A2 substrate	Non-inhibitor	0.9085
CYP450 2C9 inhibitor	Non-inhibitor	0.7994
CYP450 2D6 inhibitor	Non-inhibitor	0.8071
CYP450 2C19 inhibitor	Non-inhibitor	0.6335
CYP450 3A4 inhibitor	Inhibitor	0.5465
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8977
Ames test	Non AMES toxic	0.8008
Carcinogenicity	Non-carcinogens	0.8547
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.4704 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.9786
hERG inhibition (predictor II)	Inhibitor	0.785

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of organic compounds known as alpha amino acid amides. These are amide derivatives of alpha amino acids.

Kingdom

Organic compounds

Super Class

Organic acids and derivatives

Class

Carboxylic acids and derivatives

Sub Class

Amino acids, peptides, and analogues

Direct Parent

Alpha amino acid amides

Alternative Parents

o-Toluamides / Piperidinecarboxamides / Benzamides / Thiophenol ethers / Ortho cresols / Benzoyl derivatives / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Alkylarylthioethers / Trialkylamines

Substituents

Alpha-amino acid amide / Piperidinecarboxamide / 2-piperidinecarboxamide / Toluamide / Benzamide / O-toluamide / Benzoic acid or derivatives / Thiophenol ether / O-cresol / Benzoyl

Molecular Framework

Aromatic heteropolycyclic compounds

External Descriptors

tertiary amino compound, secondary alcohol, aryl sulfide, phenols, benzamides, organic heterobicyclic compound (CHEBI:7496 )

Targets

Details

1. HIV-1 protease

Kind: Protein
Organism: Human immunodeficiency virus
Pharmacological action: yes
Actions: inhibitor

General Function:: Aspartic-type endopeptidase activity
Specific Function:: Not Available
Gene Name:: HIV-1 protease
Uniprot ID:: O90777
Uniprot Name:: HIV-1 protease
Molecular Weight:: 10724.61 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Garriga C, Perez-Elias MJ, Delgado R, Ruiz L, Najera R, Pumarola T, Alonso-Socas Mdel M, Garcia-Bujalance S, Menendez-Arias L: Mutational patterns and correlated amino acid substitutions in the HIV-1 protease after virological failure to nelfinavir- and lopinavir/ritonavir-based treatments. J Med Virol. 2007 Nov;79(11):1617-28. [PubMed:17854027 ]
Wittayanarakul K, Hannongbua S, Feig M: Accurate prediction of protonation state as a prerequisite for reliable MM-PB(GB)SA binding free energy calculations of HIV-1 protease inhibitors. J Comput Chem. 2008 Apr 15;29(5):673-85. [PubMed:17849388 ]
Dandache S, Sevigny G, Yelle J, Stranix BR, Parkin N, Schapiro JM, Wainberg MA, Wu JJ: In vitro antiviral activity and cross-resistance profile of PL-100, a novel protease inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2007 Nov;51(11):4036-43. Epub 2007 Jul 16. [PubMed:17638694 ]
Perez MA, Fernandes PA, Ramos MJ: Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead. J Mol Graph Model. 2007 Oct;26(3):634-42. Epub 2007 Mar 24. [PubMed:17459746 ]
Velazquez-Campoy A, Kiso Y, Freire E: The binding energetics of first- and second-generation HIV-1 protease inhibitors: implications for drug design. Arch Biochem Biophys. 2001 Jun 15;390(2):169-75. [PubMed:11396919 ]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Details

1. Cytochrome P450 2C19

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:: CYP2C19
Uniprot ID:: P33261
Uniprot Name:: Cytochrome P450 2C19
Molecular Weight:: 55930.545 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

2. Cytochrome P450 3A4

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Vitamin d3 25-hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:: CYP3A4
Uniprot ID:: P08684
Uniprot Name:: Cytochrome P450 3A4
Molecular Weight:: 57342.67 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

3. Cytochrome P450 2B6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:: CYP2B6
Uniprot ID:: P20813
Uniprot Name:: Cytochrome P450 2B6
Molecular Weight:: 56277.81 Da

References

Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100-2. [PubMed:11159797 ]
Tanabe M, Hashimoto M, Ono H: Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease. Eur J Pharmacol. 2008 Jul 28;589(1-3):102-5. doi: 10.1016/j.ejphar.2008.06.013. Epub 2008 Jun 7. [PubMed:18602099 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

4. Cytochrome P450 3A5

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A5
Uniprot ID:: P20815
Uniprot Name:: Cytochrome P450 3A5
Molecular Weight:: 57108.065 Da

References

Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

5. Cytochrome P450 3A7

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitor

General Function:: Oxygen binding
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:: CYP3A7
Uniprot ID:: P24462
Uniprot Name:: Cytochrome P450 3A7
Molecular Weight:: 57525.03 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]

Details

6. Cytochrome P450 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:: CYP1A2
Uniprot ID:: P05177
Uniprot Name:: Cytochrome P450 1A2
Molecular Weight:: 58293.76 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

7. Cytochrome P450 2C9

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:: CYP2C9
Uniprot ID:: P11712
Uniprot Name:: Cytochrome P450 2C9
Molecular Weight:: 55627.365 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Details

8. Cytochrome P450 2D6

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Steroid hydroxylase activity
Specific Function:: Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:: CYP2D6
Uniprot ID:: P10635
Uniprot Name:: Cytochrome P450 2D6
Molecular Weight:: 55768.94 Da

References

Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Details

1. Serum albumin

Kind: Protein
Organism: Human
Pharmacological action: unknown

General Function:: Toxic substance binding
Specific Function:: Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:: ALB
Uniprot ID:: P02768
Uniprot Name:: Serum albumin
Molecular Weight:: 69365.94 Da

References

Bocedi A, Notaril S, Narciso P, Bolli A, Fasano M, Ascenzi P: Binding of anti-HIV drugs to human serum albumin. IUBMB Life. 2004 Oct;56(10):609-14. [PubMed:15814459 ]
Bocedi A, Notari S, Menegatti E, Fanali G, Fasano M, Ascenzi P: Allosteric modulation of anti-HIV drug and ferric heme binding to human serum albumin. FEBS J. 2005 Dec;272(24):6287-96. [PubMed:16336266 ]

Transporters

Details

1. Multidrug resistance protein 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: substrateinhibitorinducer

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:: ABCB1
Uniprot ID:: P08183
Uniprot Name:: Multidrug resistance protein 1
Molecular Weight:: 141477.255 Da

References

Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ: Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS. 2000 Jun 16;14(9):1287-9. [PubMed:10894301 ]
Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos. 2000 Jun;28(6):655-60. [PubMed:10820137 ]
Schwab D, Fischer H, Tabatabaei A, Poli S, Huwyler J: Comparison of in vitro P-glycoprotein screening assays: recommendations for their use in drug discovery. J Med Chem. 2003 Apr 24;46(9):1716-25. [PubMed:12699389 ]
Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998 Jan 15;101(2):289-94. [PubMed:9435299 ]

Details

2. Solute carrier family 22 member 1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Secondary active organic cation transmembrane transporter activity
Specific Function:: Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:: SLC22A1
Uniprot ID:: O15245
Uniprot Name:: Solute carrier family 22 member 1
Molecular Weight:: 61153.345 Da

References

Zhang L, Gorset W, Washington CB, Blaschke TF, Kroetz DL, Giacomini KM: Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos. 2000 Mar;28(3):329-34. [PubMed:10681378 ]

Details

3. Solute carrier organic anion transporter family member 1A2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:: SLCO1A2
Uniprot ID:: P46721
Uniprot Name:: Solute carrier organic anion transporter family member 1A2
Molecular Weight:: 74144.105 Da

References

Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB: OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos. 1999 Aug;27(8):866-71. [PubMed:10421612 ]

Details

4. ATP-binding cassette sub-family G member 2

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Xenobiotic-transporting atpase activity
Specific Function:: High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:: ABCG2
Uniprot ID:: Q9UNQ0
Uniprot Name:: ATP-binding cassette sub-family G member 2
Molecular Weight:: 72313.47 Da

References

Gupta A, Zhang Y, Unadkat JD, Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2004 Jul;310(1):334-41. Epub 2004 Mar 8. [PubMed:15007102 ]

Details

5. Solute carrier organic anion transporter family member 1B1

Kind: Protein
Organism: Human
Pharmacological action: unknown
Actions: inhibitor

General Function:: Sodium-independent organic anion transmembrane transporter activity
Specific Function:: Mediates the Na(+)-independent uptake of organic anions such as pravastatin, taurocholate, methotrexate, dehydroepiandrosterone sulfate, 17-beta-glucuronosyl estradiol, estrone sulfate, prostaglandin E2, thromboxane B2, leukotriene C3, leukotriene E4, thyroxine and triiodothyronine. Involved in the clearance of bile acids and organic anions from the liver.
Gene Name:: SLCO1B1
Uniprot ID:: Q9Y6L6
Uniprot Name:: Solute carrier organic anion transporter family member 1B1
Molecular Weight:: 76447.99 Da

References

Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J Pharmacol Exp Ther. 2003 Jan;304(1):223-8. [PubMed:12490595 ]

Drug created on June 13, 2005 07:24 / Updated on July 21, 2017 17:44

Get DrugBank to go!

Structure for DB00220 (Nelfinavir)

Targets

References

Enzymes

References

References

References

References

References

References

References

References

Carriers

References

Transporters

References

References

References

References

References